Michael Dybbs is listed as a director on 17 SEC Form D filings by 9 issuers between Jul 2013 and Aug 2026. Largest by amount reported sold: Samsara BioCapital, L.P. (Palo Alto, CA — pooled investment fund — 2017–2020; $310.1M reported sold to 57 investors), Delfi Diagnostics, Inc. (Palo Alto, CA — biotechnology — 2022–2025; $225M reported sold to 50 investors), Samsara Opportunity Fund, L.P. (Palo Alto, CA — pooled investment fund — 2025; $98M reported sold to 19 investors), SUTRO BIOPHARMA INC (South San Francisco, CA — biotechnology — 2018; $85.4M reported sold to 15 investors), Claris Biotherapeutics, Inc. (Half Moon Bay, CA — biotechnology — 2026; $55.7M reported sold to 14 investors) and 4 more (all listed below).
What this means A repeat sponsor — 9 separate companies raised money with this person listed as director, over about 13 years. Across those companies the filings report $931.4M sold in total.
The issuers belong to 2 sponsor groups: Aravive (2 issuers, $41.9M reported sold, 2011–2022) and Fs Analytics (2 issuers, $98M reported sold, 2023–2025).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 17 public filings for Michael Dybbs and found 11 differences, 1 worth asking the sponsor about: 4 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.